AR013090A1 - Composicion farmaceutica para el tratamiento del cancer o de un trastorno proliferativo benigno, procedimiento para el tratamiento del cancer o de untrastorno proliferativo benigno, composicion farmaceutica para inhibir el desarrollo anormal de celulas en un mamifero - Google Patents
Composicion farmaceutica para el tratamiento del cancer o de un trastorno proliferativo benigno, procedimiento para el tratamiento del cancer o de untrastorno proliferativo benigno, composicion farmaceutica para inhibir el desarrollo anormal de celulas en un mamiferoInfo
- Publication number
- AR013090A1 AR013090A1 ARP980102812A ARP980102812A AR013090A1 AR 013090 A1 AR013090 A1 AR 013090A1 AR P980102812 A ARP980102812 A AR P980102812A AR P980102812 A ARP980102812 A AR P980102812A AR 013090 A1 AR013090 A1 AR 013090A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- cancer
- proliferative disorder
- treatment
- benign proliferative
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composicion farmacéutica para el tratamiento del cáncer o de un trastorno proliferativo benigno, que comprende un inhibidor de la FTasa, uninhibidor de la HMG CoA reductasa y un vehículo farmacéuticamente aceptable, en la que elinhibi dor de la FTasa y el inhibidor de la HMG CoA reductasaestán presentes en cantidades que hacen que la composicion sea eficaz en el tratamiento del cáncer o de un trastorno proliferativo benigno. La composicionfarmacéutica mencionadacontiene por e j., sin limitarse por ello, el inhibidor de la FTasa que se selecciona de: (a) compuestos de formula (I), enla que R1 y R2 se seleccionan independientemente del grupo formado por -(CH2)p (heterociclos de 5-10 miembros),-(CH2)p(arilo C6-1 0), alilo, propargilo yalquilo C1-6, en los que p es 0 a 3, el citado alquilo y los restos alquilo de los citados grupos R1 y R2 están sustituidos opcionalmente por 1 a 3sustituyentes R9, y el arilo y los restos heterocíclicosde los citados grup os R1 y R2 están sustituidos opcionalmente por 1 a 3 sustituyentes seleccionadosindependientemente de halo y R9; R3 es -(CH2)m(1- o 2-adamantilo), -(CH2)m (cicloalquilo C3-10), -(CH2)m(arilo C6-10), alquilo C1-10, formulas(A) o (B),en los que m es 0 a 6 y los citados cicloalquilo y alquilo contienen opcionalmente 1 a 2 dobles o triples enlaces; cada uno de X1, X2 y X3 esindependientemente alquileno C1-7, que contiene opcionalmente 1 o 2 dobles o triplesenlaces, X4 es un enl ace o alquileno C1-7 que contiene opcionalmente1 o 2 dobles o triples enlaces y, en la formula (B), el resto X4 está unido al resto X1 en cualquier carbono disponible del resto X1; R4 es arilo C6-10,heterociclo de 5-10miembros o alquilo C1-6, en el que cada uno de los citados grupos R4 está sustituido opcionalmente por 1 a 3 sustituyentes R5; cada R5
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US4963897P | 1997-06-16 | 1997-06-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR013090A1 true AR013090A1 (es) | 2000-12-13 |
Family
ID=21960890
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP980102812A AR013090A1 (es) | 1997-06-16 | 1998-06-12 | Composicion farmaceutica para el tratamiento del cancer o de un trastorno proliferativo benigno, procedimiento para el tratamiento del cancer o de untrastorno proliferativo benigno, composicion farmaceutica para inhibir el desarrollo anormal de celulas en un mamifero |
Country Status (37)
Country | Link |
---|---|
EP (1) | EP0986387B1 (es) |
JP (1) | JP3713051B2 (es) |
KR (1) | KR100392573B1 (es) |
CN (1) | CN1259868A (es) |
AP (1) | AP9801261A0 (es) |
AR (1) | AR013090A1 (es) |
AT (1) | ATE235905T1 (es) |
BG (1) | BG103946A (es) |
BR (1) | BR9810616A (es) |
CA (1) | CA2294399C (es) |
CO (1) | CO4950607A1 (es) |
DE (1) | DE69812933T2 (es) |
DK (1) | DK0986387T3 (es) |
DZ (1) | DZ2518A1 (es) |
EA (1) | EA199901043A1 (es) |
ES (1) | ES2196559T3 (es) |
GT (1) | GT199800081A (es) |
HN (1) | HN1998000091A (es) |
HR (1) | HRP980328B1 (es) |
HU (1) | HUP0004624A3 (es) |
ID (1) | ID23014A (es) |
IL (1) | IL132765A0 (es) |
IS (1) | IS5259A (es) |
MA (1) | MA24569A1 (es) |
NO (1) | NO996206L (es) |
NZ (1) | NZ500662A (es) |
OA (1) | OA11231A (es) |
PA (1) | PA8453601A1 (es) |
PE (1) | PE82899A1 (es) |
PL (1) | PL337651A1 (es) |
PT (1) | PT986387E (es) |
SK (1) | SK169699A3 (es) |
TN (1) | TNSN98088A1 (es) |
TR (1) | TR199903074T2 (es) |
UA (1) | UA57081C2 (es) |
WO (1) | WO1998057633A1 (es) |
ZA (1) | ZA985182B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ID27933A (id) | 1998-05-12 | 2001-05-03 | Warner Lambert Co | Gabungan protein farnesiltransferase dan inhibitor hmg-coa reduktase serta penggunaannya untuk mengobati kanker |
WO2000016778A1 (en) * | 1998-09-24 | 2000-03-30 | Merck & Co., Inc. | A method of treating cancer |
EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
WO2000067737A2 (en) * | 1999-05-07 | 2000-11-16 | The Brigham And Women's Hospital, Inc. | USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION |
US6710058B2 (en) | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
JP2004516287A (ja) | 2000-12-19 | 2004-06-03 | ファイザー・プロダクツ・インク | 6−[(4−クロロ−フェニル)−ヒドロキシ−(3−メチル−3h−イミダゾール−4−イル)−メチル]−4−(3−エチニル−フェニル)−1−メチル−1h−キノリン−2−オン,2,3−ジヒドロキシブタン二酸塩の結晶形および製造方法 |
JP4092203B2 (ja) | 2000-12-21 | 2008-05-28 | ニトロメッド,インク. | 新規のシクロオキシゲナーゼ2選択的阻害剤としての置換アリール化合物、組成物、および使用方法 |
US20020151563A1 (en) * | 2001-03-29 | 2002-10-17 | Pfizer Inc. | Farnesyl transferase inhibitors in combination with HMG CoA reductase inhibitors for the inhibition of abnormal cell growth |
US6740757B2 (en) | 2001-08-29 | 2004-05-25 | Pfizer Inc | Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer |
TWI297606B (en) * | 2004-01-16 | 2008-06-11 | Nat Health Research Institutes | Cancer therapy |
US8168667B2 (en) | 2006-05-31 | 2012-05-01 | Galapagos Nv | Imidazolidine derivatives, uses therefor, preparation thereof and compositions comprising such |
GB2463514C (en) | 2008-09-11 | 2018-09-26 | Galapagos Nv | Imidazolidine compounds and uses therefor |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997005902A1 (fr) * | 1995-08-09 | 1997-02-20 | Banyu Pharmaceutical Co., Ltd. | Composition medicinale |
-
1998
- 1998-05-06 UA UA99126842A patent/UA57081C2/uk unknown
- 1998-06-05 EP EP98921688A patent/EP0986387B1/en not_active Expired - Lifetime
- 1998-06-05 WO PCT/IB1998/000881 patent/WO1998057633A1/en not_active Application Discontinuation
- 1998-06-05 DE DE69812933T patent/DE69812933T2/de not_active Expired - Fee Related
- 1998-06-05 HU HU0004624A patent/HUP0004624A3/hu unknown
- 1998-06-05 ES ES98921688T patent/ES2196559T3/es not_active Expired - Lifetime
- 1998-06-05 AT AT98921688T patent/ATE235905T1/de not_active IP Right Cessation
- 1998-06-05 PT PT98921688T patent/PT986387E/pt unknown
- 1998-06-05 CA CA002294399A patent/CA2294399C/en not_active Expired - Fee Related
- 1998-06-05 SK SK1696-99A patent/SK169699A3/sk unknown
- 1998-06-05 EA EA199901043A patent/EA199901043A1/ru unknown
- 1998-06-05 PL PL98337651A patent/PL337651A1/xx unknown
- 1998-06-05 TR TR1999/03074T patent/TR199903074T2/xx unknown
- 1998-06-05 JP JP50403099A patent/JP3713051B2/ja not_active Expired - Fee Related
- 1998-06-05 KR KR10-1999-7011860A patent/KR100392573B1/ko not_active IP Right Cessation
- 1998-06-05 CN CN98805968A patent/CN1259868A/zh active Pending
- 1998-06-05 BR BR9810616-3A patent/BR9810616A/pt not_active Application Discontinuation
- 1998-06-05 NZ NZ500662A patent/NZ500662A/en unknown
- 1998-06-05 DK DK98921688T patent/DK0986387T3/da active
- 1998-06-05 ID IDW991597A patent/ID23014A/id unknown
- 1998-06-05 IL IL13276598A patent/IL132765A0/xx unknown
- 1998-06-09 HN HN1998000091A patent/HN1998000091A/es unknown
- 1998-06-11 AP APAP/P/1998/001261A patent/AP9801261A0/en unknown
- 1998-06-12 AR ARP980102812A patent/AR013090A1/es unknown
- 1998-06-12 PE PE1998000500A patent/PE82899A1/es not_active Application Discontinuation
- 1998-06-15 TN TNTNSN98088A patent/TNSN98088A1/fr unknown
- 1998-06-15 ZA ZA9805182A patent/ZA985182B/xx unknown
- 1998-06-15 PA PA19988453601A patent/PA8453601A1/es unknown
- 1998-06-15 DZ DZ980128A patent/DZ2518A1/xx active
- 1998-06-15 MA MA25114A patent/MA24569A1/fr unknown
- 1998-06-15 GT GT199800081A patent/GT199800081A/es unknown
- 1998-06-16 HR HR980328A patent/HRP980328B1/xx not_active IP Right Cessation
- 1998-06-16 CO CO98034148A patent/CO4950607A1/es unknown
-
1999
- 1999-11-19 IS IS5259A patent/IS5259A/is unknown
- 1999-12-03 BG BG103946A patent/BG103946A/bg unknown
- 1999-12-10 OA OA9900276A patent/OA11231A/en unknown
- 1999-12-15 NO NO996206A patent/NO996206L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR013090A1 (es) | Composicion farmaceutica para el tratamiento del cancer o de un trastorno proliferativo benigno, procedimiento para el tratamiento del cancer o de untrastorno proliferativo benigno, composicion farmaceutica para inhibir el desarrollo anormal de celulas en un mamifero | |
RU2419626C2 (ru) | Соединения и композиции в качестве ингибиторов протеазы, активирующей каналы | |
AR035892A1 (es) | Derivados de oxazol, proceso para su preparacion, composiciones farmaceuticas que los comprenden, y el uso de dichos compuestos en la preparacion de medicamentos | |
PT96255A (pt) | Processo para a preparacao de novos derivados da 1-naftil-piperazina | |
ES2187983T3 (es) | Derivados 1,2,3,4-tetrahidronaftaleno sustituidos. | |
AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
SE8106642L (sv) | Piperazinylbensoheterocykliska foreningar och forfarande for framstellning derav | |
ES2094653T3 (es) | Derivados de indol como antagonistas de tipo 5-ht1 para uso en la migraña. | |
BR8201589A (pt) | Composto,composicao farmaceutica,processo para tratar e/ou evitar a hipertensao,insuficiencia cardiaca congestiva,arritmia,enxaqueca pertubacoes vasospasticas e asma num mamifero e processo para a preparacao de tal composto | |
AR056574A1 (es) | Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso | |
PE20040666A1 (es) | Derivados novedosos de piperidina | |
EA199801000A1 (ru) | Производные алкиламинобензотиазола и -бензоксазола | |
MX9307946A (es) | Derivados de amina secundaria ciclica, un procedimiento para su preparacion, composiciones farmaceuticas que los contienen y su uso. | |
ES2096685T3 (es) | Composicion que contiene colorantes del tipo rodacianina para el tratamiento del cancer. | |
SE8505715D0 (sv) | Indolderivat | |
MX9306310A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
PT1216245E (pt) | Derivados sulfonil-hidrazida farmaceuticamente activos | |
RU95110110A (ru) | Производные бензофурана, способ их получения, фармкомпозиция и способ лечения | |
SE7706346L (sv) | Bensaminderivat | |
FR2523965B1 (fr) | (benzimidazolyl-1)-1, n-((hydroxy-4 methoxy-3 phenyl)-2 hydroxy-2 ethyl) amino-3 butane et ses sels a activite b-adrenergique, leurs applications therapeutiques, et procede pour les preparer | |
PT92591A (pt) | Processo para a preparacao de aciloxipropanolaminas com accao bloqueadora beta--adrenergica e de composicoes farmaceuticas que as contem | |
DK432086A (da) | Fremgangsmaade til fremstilling af beta-lactamforbindelser eller saltederaf | |
RU95104235A (ru) | Агент для контроля плодовитости и содержащая его фармацевтическая композиция | |
SE7607038L (sv) | Nya antidiabetiskt aktiva isooxazolderivat | |
SE7611494L (sv) | Forfarande for framstellning av ny cyklohexylfenylderivat |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |